Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medpace Holdings, Inc. - Common Stock
(NQ:
MEDP
)
300.81
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Medpace Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
May 01, 2025
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
Via
Investor's Business Daily
Topics
Animal Testing
Economy
Government
Exposures
Animal Testing
Economy
Political
Repligen (RGEN) Q1 Earnings: What To Expect
April 28, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
Topics
World Trade
Exposures
Tariff
MEDP Q1 Earnings Call: Revenue Beats Expectations Amid Cancellations and Industry Headwinds
April 24, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance...
Via
StockStory
Topics
Earnings
Exposures
Financial
Insights into Medpace Hldgs's Upcoming Earnings
April 18, 2025
Via
Benzinga
West Pharmaceutical Services Earnings: What To Look For From WST
April 23, 2025
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting results tomorrow before market open. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Wall Street Bounces Back As Traders Shake Off Powell Jabs
April 22, 2025
Stocks are higher this afternoon, with all three major indexes bouncing back from Monday’s steep selloff.
Via
Talk Markets
Topics
Stocks / Equities
Why Medpace (MEDP) Stock Is Trading Lower Today
April 22, 2025
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 11.2% in the pre-market session after the company reported first-quarter 2025 earnings with high expectations heading into the...
Via
StockStory
Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified
April 22, 2025
The company's bookings missed expectations for the fifth consecutive quarter. Investors are questioning its "path forward."
Via
Investor's Business Daily
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect
April 22, 2025
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Via
StockStory
12 Health Care Stocks Moving In Monday's After-Market Session
April 21, 2025
Via
Benzinga
Medpace Holdings Reports Q1 Earnings, Shares Move Lower
April 21, 2025
Medpace Holdings reports first-quarter financial results after the market close on Monday. Here's a look at the key metrics from the quarter.
Via
Benzinga
Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops
April 21, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance...
Via
StockStory
Earnings Scheduled For April 21, 2025
April 21, 2025
Via
Benzinga
Medpace (MEDP) Q1 Earnings: What To Expect
April 20, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market close. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
What 5 Analyst Ratings Have To Say About Medpace Hldgs
April 14, 2025
Via
Benzinga
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
April 05, 2025
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
3 Market-Beating Stocks with Solid Fundamentals
April 01, 2025
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...
Via
StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
March 28, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
March 24, 2025
Via
Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
March 21, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.
Via
StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
March 18, 2025
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.
Via
StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
March 11, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...
Via
StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
March 05, 2025
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
2 Reasons to Watch MEDP and 1 to Stay Cautious
March 03, 2025
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period.
Via
StockStory
Topics
Stocks
Exposures
US Equities
Why Medpace (MEDP) Shares Are Trading Lower Today
February 11, 2025
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and...
Via
StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 11, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
February 10, 2025
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
February 10, 2025
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.
Via
Benzinga
Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
February 10, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s...
Via
StockStory
Earnings Scheduled For February 10, 2025
February 10, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.